Thesis
Lilly's $3.8B acquisition of a BTD psilocybin program mid-Phase 3 hinges on CVR milestones that require approval and DEA rescheduling by 2031
Eli Lilly agreed to acquire AtaiBeckley for $2.8B upfront plus up to $1.0B in CVRs, structured around BPL-003, a psilocybin analog with Breakthrough Therapy Designation that met its Phase 2b primary endpoint and has two FDA-aligned Phase 3 trials underway in treatment-resistant depression. The thesis resolves on whether BPL-003 achieves U.S. approval and DEA rescheduling by Q3 2031, as the $0.50 CVR pays only on that combined outcome. DEA scheduling of a Schedule I psychedelic outside an established precedent is the primary regulatory risk, as FDA approvability alone does not unlock the milestone.
Focus
BPL-003 Phase 3 topline data readout
early 2029
Bull
Both ReConnection-1 and ReConnection-2 demonstrate statistically significant and clinically meaningful reductions in MADRS scores at Week 4 versus placebo across the single-dose and two-dose regimens, replicating the rapid, durable symptom reduction seen in Phase 2b. Strong effect sizes and a clean safety profile would support an NDA submission on an accelerated timeline enabled by Breakthrough Therapy Designation, keeping the 2031 approval-and-rescheduling CVR milestone firmly in reach and validating Lilly's full $3.8B deal valuation.
Bear
The most likely failure modes are a statistically significant but clinically modest MADRS improvement that fails to meet pre-specified thresholds in one or both trials, or heterogeneous results between ReConnection-1 and ReConnection-2 that complicate the regulatory package. Additionally, the DEA rescheduling of psilocybin is a parallel policy dependency outside the FDA's control — even clean Phase 3 data cannot guarantee the Schedule I reclassification required to trigger the CVR by 2031, introducing a pathway risk entirely independent of clinical outcomes.
Unlock the full thesis for ATAI.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.